EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience

Zohra Chadli iD, Khadija Mansour, Ghada Jaouahdou, Manel Ben Belgacem, Yosra Soua, Nadia Ben Fredj, Jameleddine Zili, Haifa Ben Romdhane, Karim Aouam

Contact Dermatitis · 2026

DOI: 10.1111/cod.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contact Dermatitis, 2026. Verfasst von Zohra Chadli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University Hospital of Monastir, Faculty of Medicine, University of Monastir, Monastir, Tunisia. Hauptthemen laut MEDLINE: Drug Eruptions, Drug Hypersensitivity Syndrome. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identifying and discontinuing the offending drug(s) in severe cutaneous adverse drug reactions (SCARs) can be particularly challenging, especially in polymedicated patients. For many years, patch tests (PTs) were considered the only safe and reliable method for investigating SCARs. However, intradermal tests (IDTs), once thought to be contraindicated, have recently garnered increasing interest. Similarly, oral provocation tests, previously avoided due to safety concerns, are now being more frequently employed in SCAR assessment.

Methods

We analysed SCARs reported at Monastir University Hospital. Allergy work‐up included PTs, IDTs and oral provocation tests, with evaluation of cross‐reactivity, co‐sensitisation and neo‐sensitization.

Results

We identified 190 SCAR episodes in 188 patients. DRESS was most frequent (75%), followed by AGEP (19%) and SJS/TEN (6%). Causative drugs were identified in 97.9% of cases, mainly anti‐infectives. Skin tests were conducted in 69.5% of patients, yielding positivity rates of 49% for PTs and 77% for IDTs in DRESS, and 52% and 66%, respectively, in AGEP. Cross‐reactivity was noted in 7% of DRESS and 11.1% of AGEP, while neo‐sensitization was documented in 32.5% of DRESS patients.

Conclusion

Allergological investigations are valuable tools in SCAR management, enabling identification of culprit drugs, assessment of cross‐reactivity, detection of neo‐sensitization and selecting safe alternatives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug EruptionsDrug Hypersensitivity SyndromeHumansFemaleAdultMalePatch TestsMiddle AgedAdolescentYoung AdultAgedSkin TestsCross ReactionsIntradermal TestsChildAged, 80 and over

Stichwörter der Autor:innen

AGEPDRESSSCARsSJS/TENallergy work‐upintradermal testsoral provocation testspatch testsskin tests

Autor:innen und Institutionen

  • Department of Pharmacology, University Hospital of Monastir, Faculty of Medicine, University of Monastir, Monastir, Tunisia.
  • Department of Dermatology, University Hospital of Monastir, Monastir, Tunisia.

ORCID-Profile: Zohra Chadli

Zitieren

APA

Chadli, Z., Mansour, K., Jaouahdou, G., Belgacem, M. B., Soua, Y., Fredj, N. B., Zili, J., Romdhane, H. B., & Aouam, K. (2026). Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience. Contact Dermatitis. https://doi.org/10.1111/cod.70118

Vancouver

Chadli Z, Mansour K, Jaouahdou G, Belgacem MB, Soua Y, Fredj NB, et al. Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience. Contact Dermatitis. 2026. doi:10.1111/cod.70118

BibTeX
@article{Chadli2026,
  author = {Chadli, Zohra and Mansour, Khadija and Jaouahdou, Ghada and Belgacem, Manel Ben and Soua, Yosra and Fredj, Nadia Ben and Zili, Jameleddine and Romdhane, Haifa Ben and Aouam, Karim},
  title = {Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience},
  journal = {Contact Dermatitis},
  year = {2026},
  doi = {10.1111/cod.70118}
}
Kostenlos starten →